Monday, January 21, 2013

LipoScience refiles IPO, aims for up to $75 million

CED Member LipoScience is seeking between $65 and $75 million through an initial public offering, based on a filing with the SEC earlier this month.

This is the second time the firm has pursued an IPO option. The first was in a June 2011 filing.

If the IPO goes through as planned, LipoScience would trade on the Nasdaq under the symbol LPDX.

In the latest filing on Jan. 10, 2013, LipoScience set a target price between $13 and $15 a share for a total of five million shares.

The IPO arrives soon after the firm received FDA approval for a new test through its Vantera system this past September. LipoScience received FDA 510(k) clearance on its Vantera Clinical Analyzer.

LipoScience's venture capital investors include Durham-based CED Member Pappas Ventures.

No comments:

Post a Comment